Goldman Sachs
LIMN

Goldman Sachs’s Liminatus Pharma LIMN Stock Holding History

Goldman Sachs’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.44K Buy
+804
New +$6.94K ﹤0.01% 6499

Other funds holding LIMN

CCA
Cygnus Capital Advisors Atlanta, Georgia $147M AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Goldman Sachs's LIMN Position: Q2 2026 in Review

Goldman Sachs opened a new position in Liminatus Pharma (LIMN) in Q2 2026: 804 shares worth $4.44K. The stake represents ﹤0.01% of the portfolio and ranks #6499 among its holdings.

14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Goldman Sachs held 804 shares of Liminatus Pharma worth $4.44K as of Q2 2026.
  • Liminatus Pharma was a new Goldman Sachs position in Q2 2026.
  • Liminatus Pharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6499 holding.
  • 14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.